The present invention relates to a pharmaceutical composition for reducing toxic effects of ionizing radiation, the composition of one or more α, β unsaturated aryl sulfone and effective amount a) one or more water-soluble polymer about 0.5% to about 90% (w / v), b) one or more chemically-cyclodextrin from about 20% to about 60% (w / v modified by), and c) DMA about 10% to It includes: one or more components selected from the group consisting of about 50%.A specific embodiment of the pharmaceutical composition described herein and one or more α, β unsaturated aryl sulfone about 20mg / mL to about 60mg / mL 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin, hydroxyethyl-beta-cyclo dextrin modified with the at least one chemical selected from the group consisting of cyclodextrin and about 20% to about 60% (w / v), (b) povidone (povidone) one selected from the group consisting of about 0.5% to about 20% (w / v) and PEG of about 25% to about 90% (w / v) of a water-soluble polymer, and (c) at least one member selected from the group consisting of DMA from about 10% to about 50% (w / v) comprises, the composition has a pH of 7.5 to 9.2 range.A preferred embodiment of the invention the pharmaceutical composition is ON.1210.Na compound ((E) -4- carboxy-styryl -4-- chlorobenzyl sulfone sodium salt (C 16 H 12 ClNaO 4 S )) from about 30mg / mL to and to contain approximately 50mg / mL.Ionizing radiation, α, β unsaturated aryl sulfone, (E) -4- carboxy-styryl -4-- chlorobenzyl sulfone, radiotherapeutic본 발명은 이온화 방사선 독성효과 감소용 약제학적 조성물에 관한 것으로, 상기 조성물은 하나 이상의 α,β 불포화 아릴설폰 유효량과 a) 하나 이상의 수용성 중합체 약 0.5% 내지 약 90%(w/v), b) 하나 이상의 화학적으로 개질된 사이클로덱스트린 약 20% 내지 약 60%(w/v), 및 c) DMA 약 10% 내지 약 50%로 구성되는 군으로부터 선택되는 하나 이상의 성분을 포함한다.본 명세서에 기재한 약제학적 조성물의 특정 실시 형태는 하나 이상의 α,β 불포화 아릴설폰 약 20mg/mL 내지 약 60mg/mL과 2-하이드록시프로필-베타-사이클로덱스트린, 2-하이드록시프로필-감마-사이클로덱스트린, 하이드록시에틸-베타-사이클로덱스트린으로 구성되는 군 중 선택되는 하나 이상의 화학적으로 개질된 사이클로덱스트린 약 20% 내지 약 60%(w/v), (b) 포비돈(povidone) 약 0.5% 내지 약 20%(w/
